Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
about
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Advances in Cancer Immunotherapy in Solid TumorsManagement of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsA critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemiaPartial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.Computational Analysis of the Binding Specificities of PH Domains.Chronic lymphocytic leukemia therapy: new targeted therapies on the wayBruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.Ibrutinib for mantle cell lymphoma.Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.Novel agents in mantle cell lymphoma.A novel BTK gene mutation, c.82delC (p.Arg28 Alafs*5), in a Korean family with X-linked agammaglobulinemiaLong-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.On chip analysis of CNS lymphoma in cerebrospinal fluid.Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).Clinical pathways in chronic lymphocytic leukemia: Challenges and solutions.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.
P2860
Q26782633-B6ADB259-B8EB-4591-82B0-E891B51C6326Q28080113-BCCF234B-D36C-43EA-A647-C63FF162691BQ28081162-79BEC2BE-57EA-4AAA-A189-BEC3065D1197Q35794593-B9583775-E6FD-4AF7-8CD4-33E7E0D213AEQ36253983-48BFE184-1859-47F3-AEB5-EA678612CF33Q36529063-83F9CE9E-B745-44B9-9117-C937F9BD1EEFQ37113544-47F5C56B-675A-4FC5-AC0F-16CE5EF8AC0BQ38665207-27BB49DE-03C0-4823-B214-580177226912Q38694168-683D6361-C394-4430-AE51-FD0B78422ED3Q38765458-48B502C1-194E-4ED4-9407-C5DDA405AC97Q38969861-BCFD54C3-BA73-4000-BAC3-52B773F73006Q39290199-7F1B2B3B-816B-44E6-B2FD-A4C5316D05EAQ39677024-5732B578-04DC-4FEC-828F-56AA5B676BA6Q40474461-A94F62EE-6F9B-4C13-826F-2D735FA6F557Q40939528-7DBE8890-17B2-4F6E-8A14-3A238C35DB5EQ42113103-C78174AB-C4BC-448F-B8C5-8B59A7C9345CQ42503470-D011DF86-4604-4C6D-BBA4-1BE1083C446AQ47205554-33325C31-A1D3-4E61-A347-F0D4AF442F7FQ47445525-516C7B53-4EB9-49AD-B12B-281F451B6D62Q50072188-28DEF934-BA95-42C4-9C4C-8D5D29F75433Q51371549-5D42A22B-E992-4D7A-A411-11098B8E0032Q53963822-2891FB7E-4841-441B-838C-59B18810C79AQ54116803-82233B48-A0A5-42E0-B0FD-6A0437AC079D
P2860
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Bruton's tyrosine kinase: from ...... erapy for B-cell malignancies.
@en
type
label
Bruton's tyrosine kinase: from ...... erapy for B-cell malignancies.
@en
prefLabel
Bruton's tyrosine kinase: from ...... erapy for B-cell malignancies.
@en
P2860
P356
P1476
Bruton's tyrosine kinase: from ...... erapy for B-cell malignancies.
@en
P2093
Jan A Burger
Sabine Ponader
P2860
P304
P356
10.1200/JCO.2013.53.1046
P407
P577
2014-04-28T00:00:00Z